More Topics:
Human Genome Q4 Earnings Preview
Posted February 22, 2012
We Recommend...
Human Genome Sciences (NASDAQ:HGSI) is a biopharmaceutical company with a commercial focus. Monday, February 27, 2012, the company will report its fourth quarter earnings.
Expectations: Analysts are expecting the company to come in with a loss of 42 cents per share, a smaller loss than a year ago, when it reported a loss of 46 cents per share. The consensus estimate has dipped over the past three months from a loss of 41 cents. For the fiscal year, analysts are projecting a loss of $1.97 per share. The company's revenue is expected to beat the year-earlier total of $21.3 million by 100.6% to finish at $42.6 million for the quarter. The company is projected to report revenue of $128 million for the fiscal year.
Performance: Revenue has dropped in the past four quarters. It decreased 33% to $34 million in the third quarter. Prior to that, the figure fell 35.9% in the second quarter, 42.9% in the first quarter and 59.8% in the fourth quarter of the last fiscal year. The stock price has risen from $7.03 on November 25, 2011 to $8.92 over the past quarter. Human Genome's best recent streak was when its price gained $1.87 per share between January 17, 2012 and January 30, 2012.
Ratings: The majority of analysts (60%) give the stock a buy rating. However, that is lower than the average analyst ratings for the comapny's 10 closest competitors, which average 61.2% buys. Analysts are slightly more optimistic about the stock recently, as the number of buy ratings has risen slightly over the past three months.
Earnings estimates provided by Zacks.
To find out more about the company in this article and to see if you
have business connections, click below:
blog comments powered by